Market Place
Sourcing Support
Menarini Group Announces Positive Obicetrapib Trial Data
16 Dec 2024 //
PR NEWSWIRE
NewAmsterdam shares sign drug improves cardiovascular outcomes
11 Dec 2024 //
FIERCE BIOTECH
NewAmsterdam Pharma Announces Positive Obicetrapib Phase 3 Data
10 Dec 2024 //
GLOBENEWSWIRE
Menarini`s Obicetrapib Phase 3 Trial Positive For Familial Hypercholesterolemia
29 Jul 2024 //
PR NEWSWIRE
NewAmsterdam Completes Enrollment For Obicetrapib-Ezetimibe Combo TANDEM Trial
08 Jul 2024 //
GLOBENEWSWIRE
NewAmsterdam Announces Issuance of Composition of Matter Patent for Obicetrapib
11 Jun 2024 //
GLOBENEWSWIRE
NewAmsterdam To Present Obicetrapib Cardio Risk Data
21 May 2024 //
GLOBENEWSWIRE
NewAmsterdam Enrolls 9,000+ patients in Trial
09 Apr 2024 //
GLOBENEWSWIRE
NewAmsterdam #Doses First Patient in Phase 3 Evaluating Obicetrapib & Ezetimibe
12 Mar 2024 //
GLOBENEWSWIRE
NewAmsterdam Announces Initial Data from Phase 2a Trial Evaluating Obicetrapib
21 Sep 2023 //
GLOBENEWSWIRE
Could obicetrapib facilitate sufficient LDL-cholesterol levels?
28 Jun 2023 //
EUROPEAN PHARMACEUTICAL REVIEW
NewAmsterdam Announces Results from Phase 2b Trial Evaluating Obicetrapib
05 Jun 2023 //
GLOBENEWSWIRE
NewAmsterdam Presents Full Data from Phase 2 ROSE2 Trial Evaluating Obicetrapib
03 Jun 2023 //
GLOBENEWSWIRE
NewAmsterdam Pharma Completes Enrollment in Pivotal Ph3
24 Apr 2023 //
GLOBENEWSWIRE
NewAmsterdam notches another win in resurrection of Amgen cardio drug
18 Jan 2023 //
ENDPTS
NewAmsterdam Pharma Announces Initiation of Phase 2 Dose-Finding Study
05 Oct 2022 //
BUSINESSWIRE
NewAmsterdam Pharma Announces Publication in Nature Medicine
11 Aug 2022 //
BUSINESSWIRE
Newamsterdam secures €1B-plus European commercial deal with Menarini
29 Jun 2022 //
BIOWORLD
NewAmsterdam Pharma Begins Dosing in Phase 2 Trial of Obicetrapib + zetimibe
05 Apr 2022 //
BUSINESSWIRE
NewAmsterdam Pharma Doses First Patient in PREVAIL, Trial of Obicetrapib
01 Mar 2022 //
BUSINESSWIRE
NewAmsterdam Pharma Doses First Patient in Phase 3 BROADWAY Trial of Obicetrapib
04 Jan 2022 //
BUSINESSWIRE
NewAmsterdam Pharma Presents Full Results from Ph2 ROSE Study of Obicetrapib
13 Nov 2021 //
BUSINESSWIRE
A Forbion-funded startup bought the rights to Amgen`s CETP inhibitor
28 Aug 2020 //
ENDPTS
A new biotech forms to revive Amgen`s old heart drug
26 Aug 2020 //
BIOPHARMADIVE
NewAmsterdam Pharma Acquires Obicetrapib from Amgen
25 Aug 2020 //
BIOSPACE
NewAmsterdam Pharma Acquires Obicetrapib from Amgen
25 Aug 2020 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.